Literature DB >> 28931488

Carboxylate cross-linked cyclodextrin: A nanoporous scaffold for enhancement of rosuvastatin oral bioavailability.

Mai Mahmoud Gabr1, Sana Mohamed Mortada2, Marwa Ahmed Sallam3.   

Abstract

Cyclodextrins play an important role in supramolecular chemistry acting as building blocks than can be cross-linked by various linker molecules forming nano-porous structures called nanosponges (NS). NS have the ability to enhance the stability, solubility and bioavailability of various actives. This work aimed at elaborating rosuvastatin (ROS) loaded NS to improve its oral bioavailability. Carboxylate-linked NS were synthesized by reacting β-CD with pyromellitic dianhydride (PDA) at different molar ratios under specific conditions. ROS-loaded NS were prepared by lyophilisation technique and characterized for particle size, zeta potential, entrapment efficiency and drug release. Occurrence of cross-linking and ROS incorporation within the NS were assessed by DSC, FT-IR and SEM micrographs. NS prepared at a molar ratio of 1:6 of β-CD: PDA demonstrated the highest entrapment efficiency (88.76%), an optimum particle size of 275nm, a narrow size distribution (PDI of 0.392), and zeta potential of -61.9 indicating good colloidal stability. In vivo oral pharmacokinetics study in male Sprague Dawley rats showed that ROS-NS provided an outstanding enhancement in oral bioavailability compared to drug suspension and marketed tablets besides their physicochemical stability for 3month. Accordingly, ROS-NS represent a superior alternative to the conventional marketed formulation for effective ROS delivery.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cross-linking; Cyclodextrin; Oral bioavailability; Porous; Pyromellitic dianhydride; Rosuvastatin

Mesh:

Substances:

Year:  2017        PMID: 28931488     DOI: 10.1016/j.ejps.2017.09.026

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Directly compressed rosuvastatin calcium tablets that offer hydrotropic and micellar solubilization for improved dissolution rate and extent of drug release.

Authors:  Sharonia Butt; Syed Muhammad Farid Hasan; Muhammad Mohtasheemul Hassan; Khalid M Alkharfy; Steven Henry Neau
Journal:  Saudi Pharm J       Date:  2019-05-08       Impact factor: 4.330

2.  Oral Bioavailability Improvement of Tailored Rosuvastatin Loaded Niosomal Nanocarriers to Manage Ischemic Heart Disease: Optimization, Ex Vivo and In Vivo Studies.

Authors:  Kun Liao; Na Tang; Qiang Liu; Jing Xu
Journal:  AAPS PharmSciTech       Date:  2021-01-27       Impact factor: 4.026

3.  Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign.

Authors:  Doaa H Alshora; Mohamed A Ibrahim; Ehab Elzayat; Osaid T Almeanazel; Fars Alanazi
Journal:  PLoS One       Date:  2018-07-09       Impact factor: 3.240

4.  Defining the process parameters affecting the fabrication of rosuvastatin calcium nanoparticles by planetary ball mill.

Authors:  Doaa Alshora; Mohamed Ibrahim; Ehab Elzayat; Osaid T Almeanazel; Fars Alanazi
Journal:  Int J Nanomedicine       Date:  2019-06-27

Review 5.  Cyclodextrin-Based Nanosponges: Overview and Opportunities.

Authors:  Gianluca Utzeri; Pedro M C Matias; Dina Murtinho; Artur J M Valente
Journal:  Front Chem       Date:  2022-03-24       Impact factor: 5.221

6.  Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model.

Authors:  Jun Li; Min Yang; Wenrong Xu
Journal:  Drug Des Devel Ther       Date:  2018-07-20       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.